{"filing":{"accession_number":"0001193125-26-258417","cik":"0001776111","ticker":"MBX","company_name":"MBX Biosciences, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"mbx-20260604.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526258417/mbx-20260604.htm"},"events":[{"id":3661,"run_id":3211,"accession_number":"0001193125-26-258417","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"MBX Biosciences held its 2026 Annual Meeting on June 4, 2026, at which stockholders approved the election of two Class II directors (Patrick J. Heron and Edward T. Mathers) for three-year terms and ratified Ernst \u0026 Young LLP as the company's independent auditor.","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-06-05","items":[{"id":4657,"accession_number":"0001193125-26-258417","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Item 5.02 section discloses the outcome of stockholder voting at the 2026 annual meeting, specifically the approval of two Class II directors for three-year terms. While Item 5.02 typically covers executive departures and appointments, the substance here is the shareholder vote result itself, which is the material event. The cross-reference to Item 5.07 confirms this is primarily a shareholder vote disclosure, making shareholder_vote_results the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:49:37.376184+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4658,"accession_number":"0001193125-26-258417","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of MBX Biosciences' Annual Meeting held on June 4, 2026, including stockholder votes on two proposals: (i) election of two Class II director nominees (Patrick J. Heron and Edward T. Mathers) and (ii) ratification of Ernst \u0026 Young LLP as independent auditor. The filing provides detailed vote tallies for each proposal, which is the core content of a shareholder vote results disclosure. Both proposals were approved by stockholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:49:37.376184+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4657,"accession_number":"0001193125-26-258417","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Item 5.02 section discloses the outcome of stockholder voting at the 2026 annual meeting, specifically the approval of two Class II directors for three-year terms. While Item 5.02 typically covers executive departures and appointments, the substance here is the shareholder vote result itself, which is the material event. The cross-reference to Item 5.07 confirms this is primarily a shareholder vote disclosure, making shareholder_vote_results the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:49:37.376184+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-06-05"},{"id":4658,"accession_number":"0001193125-26-258417","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of MBX Biosciences' Annual Meeting held on June 4, 2026, including stockholder votes on two proposals: (i) election of two Class II director nominees (Patrick J. Heron and Edward T. Mathers) and (ii) ratification of Ernst \u0026 Young LLP as independent auditor. The filing provides detailed vote tallies for each proposal, which is the core content of a shareholder vote results disclosure. Both proposals were approved by stockholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:49:37.376184+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-06-05"}]}